Search Results for "Adipex-P"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Adipex-P. Results 1 to 5 of 5 total matches.
See also: phentermine

In Brief: Phentermine (Lomaira) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016  (Issue 1509)
for obesity: a systematic and clinical review. JAMA 2014; 311:74.The Medical Letter Adipex-P Lomaira ...
The FDA has approved Lomaira (KVK Tech), an 8-mg tablet formulation of phentermine that can be taken up to three times daily before meals, as an adjunct to lifestyle modifications for weight loss. It is only approved for short-term use (a few weeks) in adults with a body mass index (BMI) ≥30 kg/m2, or with a BMI ≥27 kg/m2 in addition to a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes. Phentermine has been available alone and in combination with topiramate for years.1Lomaira was approved by the FDA under an abbreviated new drug application (ANDA) and is...
Med Lett Drugs Ther. 2016 Dec 5;58(1509):158 |  Show IntroductionHide Introduction

Contrave - A Combination of Bupropion and Naltrexone for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014  (Issue 1455)
– generic 15, 30, 37.5 mg caps, 37.5 mg tabs 15-37.5 mg once/d 20.20 Adipex-P (Teva) 37.5 mg tabs, caps ...
The FDA has approved a fixed-dose combination of the opioid receptor antagonist naltrexone (ReVia, and others) and the antidepressant and smoking cessation agent bupropion (Wellbutrin SR, Zyban, and others), as Contrave (Orexigen/Takeda) for weight loss. The combination was approved for use as an adjunct to diet and increased physical activity in patients with a body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2 and one or more weight-related comorbidities such as hypertension, diabetes, or dyslipidemia. Naltrexone/bupropion is not a controlled...
Med Lett Drugs Ther. 2014 Nov 10;56(1455):112-4 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Weight Management (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
Phentermine – generic Adipex-P (Teva) Lomaira (KVK-Tech) 15, 30, 37.5 mg caps; 37.5 mg tabs 37.5 mg caps ...
View the Comparison Table: Some Drugs for Weight Management
Med Lett Drugs Ther. 2025 Aug 4;67(1734):e127-30   doi:10.58347/tml.2025.1734b |  Show IntroductionHide Introduction

Two Drugs for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Sep 03, 2012  (Issue 1398)
19.50 Adipex-P (Teva) 37.5 mg tabs 37.5 mg once 62.70 Suprenza (Akrimax) 15, 30 mg ODT 15-30 mg once ...
In 2013 the FDA approved one new drug and a new combination of 2 old drugs as adjuncts to lifestyle changes for chronic weight management. Lorcaserin (lor-ca-SER-in; Belviq – Arena/Esai) is a selective serotonin 2C receptor agonist. Qsymia (Vivus) is a fixed-dose combination of the weight-loss drug phentermine and an extended-release (ER) formulation of topiramate. The new products are approved for use in obese patients (body mass index [BMI] of ≥30 kg/m2) and for patients who are overweight (BMI ≥27 kg/m2) and have one weight-related risk factor such as hypertension, dyslipidemia or...
Med Lett Drugs Ther. 2012 Sep 3;54(1398):69-71 |  Show IntroductionHide Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
once/day See footnote 11 7.40 37.5 mg tabs Adipex-P (Teva) 37.5 mg caps, tabs 37.5 mg PO once/day See ...
Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone before adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8   doi:10.58347/tml.2025.1734a |  Show IntroductionHide Introduction